
Feb 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Albemarle, Moderna and Newmont, on Monday.
HIGHLIGHTS
Albemarle ALB.N: RBC raises target price to $216 from $200 |
Moderna MRNA.O: RBC raises target price to $30 from $25 |
Newmont NEM.N: Jefferies raises target price to $158 from $136 |
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.
Albemarle ALB.N: RBC raises target price to $216 from $200 |
Cognex Corp CGNX.O: Daiwa Capital Markets raises target price to $65 from $45 |
Dupont DD.N: RBC raises target price to $60 from $51 |
Eagle Materials Inc EXP.N: JP Morgan cuts target price to $215 from $230 |
Eagle Materials Inc EXP.N: JP Morgan cuts to underweight from neutral |
Expedia Group Inc EXPE.O: Jefferies cuts target price to $240 from $285 |
Maplebear Inc CART.O: Jefferies cuts target price to $38 from $44 |
Moderna MRNA.O: Jefferies raises target price to $37 from $30 |
Moderna MRNA.O: RBC raises target price to $30 from $25 |
Newmont NEM.N: Jefferies raises target price to $158 from $136 |
Royal Gold Inc RGLD.O: Jefferies raises target price to $390 from $320 |